[144] VERACYTE, INC. SEC Filing

Rhea-AI Filing Summary

Veracyte, Inc. filed a Form 144 reporting a proposed sale of 2,539 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/01/2025. The filing lists an aggregate market value of $87,163.87 based on 78,671,588 shares outstanding. The shares were acquired on 03/02/2024 as restricted stock units issued by the company and were paid on that same date. The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information regarding the issuer.

Positive

• Use of a major broker: The sale is routed through Morgan Stanley Smith Barney LLC, indicating standard market handling.
• Clear acquisition history: Shares were acquired as restricted stock units on 03/02/2024 and fully paid the same day, documented in the filing.
• No recent sales: The filer reports "Nothing to Report" for securities sold during the past three months.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider notice: a small-volume sale request via a major broker, likely administrative rather than material to the company.

The Form 144 documents a proposed sale of 2,539 common shares with an aggregate market value of $87,163.87, executed through Morgan Stanley Smith Barney and slated for 10/01/2025. The shares originated from restricted stock units granted by the issuer on 03/02/2024 and were paid the same day. There are no reported sales in the prior three months. From a market-impact perspective, the size of the position relative to 78,671,588 outstanding shares is immaterial and the filing follows required disclosure norms.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing an insider sale plan and the filer’s certification of no undisclosed material information.

The notice includes the filer’s representation that they do not possess undisclosed material adverse information. It also records that the securities were acquired as restricted stock units from the issuer on 03/02/2024. The document contains standard Rule 144 disclosures and a broker designation, indicating adherence to transfer and sale procedures. No governance irregularities or missing mandatory disclosures are evident within the text provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2539	87163.87	78671588	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/02/2024	Restricted Stock Units	Issuer			2539	03/02/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Veracyte (VCYT) report in this Form 144?

The filing reports a proposed sale of 2,539 common shares via Morgan Stanley Smith Barney on NASDAQ, approximate sale date 10/01/2025.

What is the aggregate market value and shares outstanding stated?

The aggregate market value is $87,163.87 and the filing lists 78,671,588 shares outstanding.

How were the shares acquired according to the filing?

The shares were acquired on 03/02/2024 as restricted stock units from the issuer, with the payment date also 03/02/2024.

Did the filer report any securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer assert possession of any undisclosed material information?

By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.